DANVERS, Mass.--(BUSINESS WIRE)--Data from more than 1,000 patients presented during the virtual 2020 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions demonstrates ...
BOSTON--(BUSINESS WIRE)--Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of ...
Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. PROTECT ...
Impella devices have been the subjects of a series of Abiomed letters and FDA early alerts and recall notices. In January, Abiomed sent an urgent medical device correction about a malfunction risk ...
PHILADELPHIA -- The Impella mechanical support device, frequently used in patients in cardiogenic shock who are undergoing percutaneous coronary interventions, was more expensive than intra-aortic ...
Compared with no added support, use of the Impella percutaneous left ventricular assist device (Abiomed) in patients undergoing high-risk nonemergent PCI is associated with more periprocedural MI ...
WASHINGTON, DC—A protocol focusing on early use of the Impella ventricular support device (Abiomed) in patients with acute MI complicated by cardiogenic shock may help lower the stubbornly high ...
DANVERS, Mass.--(BUSINESS WIRE)-- The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart ...
DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S.
DANVERS, Mass. – Nov. 27, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- A ...
PHILADELPHIA — Interventional cardiology has taken quite a shine to Impella ventricular assist pumps (Abiomed) for cardiogenic shock (CS) and to support high-risk procedures, but two new observational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results